Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has joined the NVIDIA Developer Program which is expected to enhance and advance its AI agent integration platform.  

QwikAgents’ AI-agent platform is designed to automate complex workflows through autonomous AI agents capable of reasoning, taking action, and interacting with business systems. The platform incorporates persistent memory, intelligent model routing across multiple large language model providers, browser automation, and secure data management to support scalable AI-driven operations.

Through the NVIDIA Developer Program, QwikAgents will gain access to NVIDIA's AI software ecosystem, development frameworks, technical training, and optimization resources that support the development and deployment of next-generation AI applications. These resources could help accelerate enhancements to the QwikAgents platform as it seeks to expand capabilities for enterprise customers seeking to integrate autonomous AI agents into their operations.